Continuous dopaminergic stimulation therapy for Parkinson's disease - Recent advances
Timpka, Jonathan LU ; Mundt-Petersen, Ulrika LU and Odin, Per LU
(2016)
In Current Opinion in Neurology
29(4).
p.474-479
- Abstract
Purpose of review We aim to review the most interesting recent advances on the clinical aspects of continuous dopaminergic stimulation in Parkinson's disease. Recent findings Several large, open-label studies have presented data that are in line with the randomized controlled trial on L-dopa-carbidopa intestinal gel infusion, which shows that a continuous drug delivery can improve motor fluctuations and dyskinesia in patients with advanced Parkinson's disease. Furthermore, new extended-release formulations of L-dopa aim to stabilize plasma concentrations and thus reduce the degree of motor complications - despite a reduced number of daily doses. Transdermal rotigotine has been shown to be effective for specific subgroups of patients,... (More)
Purpose of review We aim to review the most interesting recent advances on the clinical aspects of continuous dopaminergic stimulation in Parkinson's disease. Recent findings Several large, open-label studies have presented data that are in line with the randomized controlled trial on L-dopa-carbidopa intestinal gel infusion, which shows that a continuous drug delivery can improve motor fluctuations and dyskinesia in patients with advanced Parkinson's disease. Furthermore, new extended-release formulations of L-dopa aim to stabilize plasma concentrations and thus reduce the degree of motor complications - despite a reduced number of daily doses. Transdermal rotigotine has been shown to be effective for specific subgroups of patients, although the general effect on nonmotor symptoms is still unclear. New products for L-dopa infusion are also at different stages of development, but the routes of administration are widely different: intrajejunal, subcutaneous, and oral. Summary The understanding of the mechanisms behind the complications of long-term L-dopa treatment is still not complete, but therapies aiming for continuous dopaminergic stimulation are already widely used in clinical practice and the evidence strength is improving. However, there is still an urgent need for both less invasive and less costly options in order to increase access to these therapies.
(Less)
- author
- Timpka, Jonathan
LU
; Mundt-Petersen, Ulrika
LU
and Odin, Per
LU
- organization
- publishing date
- 2016-08-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- antiparkinson agents, continuous dopaminergic stimulation, continuous drug delivery, drugs, investigational, Parkinson's disease
- in
- Current Opinion in Neurology
- volume
- 29
- issue
- 4
- pages
- 6 pages
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- pmid:27272976
- wos:000379207400011
- scopus:84973299611
- ISSN
- 1350-7540
- DOI
- 10.1097/WCO.0000000000000354
- language
- English
- LU publication?
- yes
- id
- 7fe67912-25a9-41b6-a2e2-efc5504881bb
- date added to LUP
- 2016-07-19 07:34:38
- date last changed
- 2024-01-04 10:08:17
@article{7fe67912-25a9-41b6-a2e2-efc5504881bb,
abstract = {{<p>Purpose of review We aim to review the most interesting recent advances on the clinical aspects of continuous dopaminergic stimulation in Parkinson's disease. Recent findings Several large, open-label studies have presented data that are in line with the randomized controlled trial on L-dopa-carbidopa intestinal gel infusion, which shows that a continuous drug delivery can improve motor fluctuations and dyskinesia in patients with advanced Parkinson's disease. Furthermore, new extended-release formulations of L-dopa aim to stabilize plasma concentrations and thus reduce the degree of motor complications - despite a reduced number of daily doses. Transdermal rotigotine has been shown to be effective for specific subgroups of patients, although the general effect on nonmotor symptoms is still unclear. New products for L-dopa infusion are also at different stages of development, but the routes of administration are widely different: intrajejunal, subcutaneous, and oral. Summary The understanding of the mechanisms behind the complications of long-term L-dopa treatment is still not complete, but therapies aiming for continuous dopaminergic stimulation are already widely used in clinical practice and the evidence strength is improving. However, there is still an urgent need for both less invasive and less costly options in order to increase access to these therapies.</p>}},
author = {{Timpka, Jonathan and Mundt-Petersen, Ulrika and Odin, Per}},
issn = {{1350-7540}},
keywords = {{antiparkinson agents; continuous dopaminergic stimulation; continuous drug delivery; drugs; investigational; Parkinson's disease}},
language = {{eng}},
month = {{08}},
number = {{4}},
pages = {{474--479}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{Current Opinion in Neurology}},
title = {{Continuous dopaminergic stimulation therapy for Parkinson's disease - Recent advances}},
url = {{http://dx.doi.org/10.1097/WCO.0000000000000354}},
doi = {{10.1097/WCO.0000000000000354}},
volume = {{29}},
year = {{2016}},
}